CLOs on the Move

Univercells

www.univercells.com

 
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines - for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost. The company`s process intensification and integration technology entails smaller footprint and unit cost while offering flexible capabilities, from small to large batches. Deployment of affordable production units enables `in-country, for-country` biologics production, creating value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients` access to healthcare. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.univercells.com
  • 4775 Collins Avenue Suite 1604
    Miami Beach, FL USA 33140
  • Phone: 786.276.7817

Executives

Name Title Contact Details

Similar Companies

Cereset

#Cereset is a wellness company that helps their clients relax their #brain to manage stress and achieve restful #sleep. 🧠💤 Centers across the US & Europe.

Hess Associates

Hess Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Athenix

Athenix Corp. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedWorxs

MedWorxs is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.